Inventiva announces participation at several conferences in March 2022
March 01 2022 - 4:00PM
Daix (France), Long Island
City (New York, United States), March 1, 2022 – Inventiva
(Euronext Paris and Nasdaq: IVA), a clinical-stage
biopharmaceutical company focused on the development of oral small
molecule therapies for the treatment of non-alcoholic
steatohepatitis (NASH) and other diseases with significant unmet
medical needs, announced that the Company’s leadership will
participate in two upcoming investor conferences in March 2022.
The event details are as follows:
Conference n°1: Event
type: Date:Corporate
presentation:Format:Live and
replay link: |
Cowen 42nd
Annual Health Care ConferenceCorporate presentation and one-on-one
investors meetingsMonday-Wednesday, March 7-9, 2022Monday, March 7,
12:50 pm – 1:20 pm (ET) / 6:50 pm – 7:20 pm (CET)Virtual
eventhttps://wsw.com/webcast/cowen108/iva/1843488 |
|
|
Conference n°2:Event
type:Date: Time: Format:Location: |
Invest securities Biomed EventOne-on-one investor meetings
Tuesday, March 8, 20223:00 am – 12:00 am (ET) / 9:00 am– 6:00 pm
(CET)In-person eventSalons Hoche, 9 avenue Hoche, 75008 Paris,
France |
The link to the event will also be available on
Inventiva’s website in the “Investors – Investor Presentations”
section.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of NASH and other diseases with significant unmet
medical need.
Leveraging its expertise and experience in the
domain of compounds targeting nuclear receptors, transcription
factors and epigenetic modulation, Inventiva is currently advancing
lanifibranor, as well as other earlier stage programs.
Lanifibranor, Inventiva’s lead product
candidate, is being developed for the treatment of patients with
NASH, a common and progressive chronic liver disease for which
there are currently no approved therapies. In 2020, Inventiva
announced positive topline data from its Phase IIb clinical trial
evaluating lanifibranor for the treatment of adult patients with
NASH and obtained both FDA Breakthrough Therapy and Fast Track
designation for lanifibranor in the treatment of NASH. Lanifibranor
is currently being evaluated in a pivotal Phase III clinical
trial.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of patients with subtypes of MPS,
a group of rare genetic disorders. Inventiva announced positive
topline data from its Phase IIa clinical trial evaluating odiparcil
for the treatment of adult MPS VI patients in 2019 and received
both FDA Fast Track and Rare Paediatric Disease designation for
odiparcil in MPS VI. As part of Inventiva’s decision to focus
clinical efforts on the development of lanifibranor, it suspended
clinical efforts relating to odiparcil and is reviewing all
available options to optimize its development.
The Company has also established a strategic
collaboration with AbbVie in the area of autoimmune diseases
resulting in the discovery of the drug candidate cedirogant
(ABBV-157), an oral RORg inverse agonist. Cedirogant showed
promising activity as an oral psoriasis agent in a Phase Ib
clinical trial of patients with chronic plaque psoriasis and is
currently being evaluated in a Phase IIb clinical trial in patients
with moderate to severe chronic plaque psoriasis. This
collaboration enables Inventiva to receive payments upon the
achievement of pre-clinical, clinical, regulatory and commercial
milestones, in addition to royalties on any approved products
resulting from this collaboration.
In parallel, Inventiva is in the process of
selecting an oncology development candidate for its Hippo
signalling pathway program.
The Company has a scientific team of
approximately 70 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, as well as in clinical development. It also owns
an extensive library of approximately 240,000 pharmacologically
relevant molecules, approximately 60% of which are proprietary, as
well as a wholly‑owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com.
Contacts
InventivaPascaline ClercVP of Global External
Affairs media@inventivapharma.com+1 240 620 9175 |
Brunswick GroupLaurence Frost /Tristan Roquet
Montegon /Aude LepreuxMedia
relationsinventiva@brunswickgroup.com+33 1 53 96 83 83 |
Westwicke,
an ICR CompanyPatricia L. Bank Investor
relationspatti.bank@westwicke.com+1 415 513 1284 |
|
|
|
- Inventiva - PR - March IR events - 29 02 2022
Inventiva (EU:IVA)
Historical Stock Chart
From May 2024 to Jun 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Jun 2023 to Jun 2024